Glotz D, et al. - Researchers reported the results of an open-label, single-arm trial that examined eculizumab regarding its safety and efficacy in preventing acute antibody-mediated rejection (AMR) in recipients of deceased-donor kidney transplants with preformed donor-specific antibodies. Eculizumab was administered to participants as follows: 1200 mg immediately before reperfusion, 900 mg on posttransplantation days 1, 7, 14, 21 and 28, and 1200 mg at weeks 5, 7 and 9. Graft and patient survival were 83.4% and 91.5%, respectively, at 36 months. Patients well-tolerated eculizumab and displayed no new safety concerns. Findings thus suggest the potential of eculizumab in providing prophylaxis against injury caused by acute AMR in such patients.